Published in Diabetes on November 01, 2009
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res (2015) 0.85
Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism. Sci Rep (2016) 0.75
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia (2009) 7.06
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia (2009) 3.89
Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia (2009) 3.82
Does diabetes therapy influence the risk of cancer? Diabetologia (2009) 3.66
Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology (2001) 3.38
Insulin glargine and malignancy: an unwarranted alarm. Lancet (2009) 3.19
Insulin glargine and cancer--an unsubstantiated allegation. Diabetes Technol Ther (2009) 1.09
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes (2003) 16.62
Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes (2008) 5.23
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology (2011) 4.99
High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes (2007) 2.96
Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev (2008) 2.79
Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 2.61
Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care (2006) 2.46
Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes (2004) 2.20
β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care (2012) 2.20
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes (2009) 2.10
Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care (2006) 2.03
11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med (2009) 1.99
Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes (2006) 1.87
Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab (2011) 1.83
Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide. Am J Physiol Endocrinol Metab (2007) 1.80
Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes (2005) 1.73
Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes (2007) 1.57
Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol (2009) 1.53
Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab (2006) 1.47
Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. ILAR J (2006) 1.45
GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care (2010) 1.45
Rb and p130 control cell cycle gene silencing to maintain the postmitotic phenotype in cardiac myocytes. J Cell Biol (2011) 1.42
Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes (2006) 1.40
Autophagy defends pancreatic β cells from human islet amyloid polypeptide-induced toxicity. J Clin Invest (2014) 1.37
Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes (2012) 1.32
Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress. Diabetes (2009) 1.23
Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol (2008) 1.22
Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes (2006) 1.16
Measurement of pulsatile insulin secretion in the rat: direct sampling from the hepatic portal vein. Am J Physiol Endocrinol Metab (2008) 1.15
Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes (2003) 1.12
β-cell dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptide-induced UCH-L1 deficiency. Diabetes (2010) 1.10
Ongoing beta-cell turnover in adult nonhuman primates is not adaptively increased in streptozotocin-induced diabetes. Diabetes (2011) 1.09
Inconsistent formation and nonfunction of insulin-positive cells from pancreatic endoderm derived from human embryonic stem cells in athymic nude rats. Am J Physiol Endocrinol Metab (2010) 1.09
Calcium-activated calpain-2 is a mediator of beta cell dysfunction and apoptosis in type 2 diabetes. J Biol Chem (2009) 1.08
β-Cell failure in type 2 diabetes: a case of asking too much of too few? Diabetes (2013) 1.06
Pulsatile insulin secretion by human pancreatic islets. J Clin Endocrinol Metab (2002) 1.04
Adaptations in pulsatile insulin secretion, hepatic insulin clearance, and beta-cell mass to age-related insulin resistance in rats. Am J Physiol Endocrinol Metab (2008) 1.03
The potential for stem cell therapy in diabetes. Pediatr Res (2006) 1.02
Glucose stimulates pulsatile insulin secretion from human pancreatic islets by increasing secretory burst mass: dose-response relationships. J Clin Endocrinol Metab (2003) 1.01
Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway. J Clin Endocrinol Metab (2005) 1.00
Intrahepatic transplanted islets in humans secrete insulin in a coordinate pulsatile manner directly into the liver. Diabetes (2006) 0.98
Hematopoietic stem cells derived from adult donors are not a source of pancreatic beta-cells in adult nondiabetic humans. Diabetes (2007) 0.97
Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Endocrinology (2003) 0.96
Development of factors to convert frequency to rate for beta-cell replication and apoptosis quantified by time-lapse video microscopy and immunohistochemistry. Am J Physiol Endocrinol Metab (2008) 0.95
Many commercially available antibodies for detection of CHOP expression as a marker of endoplasmic reticulum stress fail specificity evaluation. Cell Biochem Biophys (2008) 0.95
Cyclin-dependent kinase 5 promotes pancreatic β-cell survival via Fak-Akt signaling pathways. Diabetes (2011) 0.94
Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab (2004) 0.93
The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity. Amyloid (2010) 0.92
Pancreatic fat content and beta-cell function in men with and without type 2 diabetes: response to Tushuizen et al. Diabetes Care (2008) 0.88
Dynamics of beta-cell turnover: evidence for beta-cell turnover and regeneration from sources of beta-cells other than beta-cell replication in the HIP rat. Am J Physiol Endocrinol Metab (2009) 0.87
Effects of fasting on physiologically pulsatile insulin release in healthy humans. Diabetes (2002) 0.85
Annexin A5 directly interacts with amyloidogenic proteins and reduces their toxicity. Biochemistry (2009) 0.81
Glucagonlike Peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer? JAMA Intern Med (2013) 0.81
Response to Comment on: Saisho et al. β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 2013;36:111-117. Diabetes Care (2013) 0.76
Beta-cell selective K(ATP)-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity. Regul Pept (2010) 0.76
Shortened {beta}-cell lifespan leads to {beta}-cell deficit in a rodent model of type 2 diabetes. Am J Physiol Endocrinol Metab (2011) 0.75
Farewell statement from Dr. Peter Butler as outgoing editor in chief of diabetes. Diabetes (2011) 0.75